Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quarterly results round-up: LabCorp, Bard hit by legal costs; Edwards, Intuitive grow top and bottom lines

This article was originally published in Clinica

Executive Summary

CR Bard swung to a net loss of $47.8m in its fiscal second quarter as it absorbed $195.5m in litigation charges related to its recalled hernia products. The products include the Composix Kugel mesh hernia patch, which its Davol subsidiary recalled in 2006 due to a risk of the patch breaking and damaging patients' internal organs (www.clinica.co.uk, 10 March 2006).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel